Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime/nacubactam and aztreonam/nacubactam versus best available therapy for carbapenem-resistant Enterobacterales infections
2024-515180-56-00Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Aug 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, single-blind trial of cefepime, Nacubactam and aztreonam in complicated urinary tract infection (cUTI), acute pyelonephritis, hospital-acquired pneumonia (HAP) and 3 more (3 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Overall treatment success at test of cure across all infection types. Started Aug 2024; status: completed.
02
Drugs
cefepimeNacubactamaztreonam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritishospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2024-515180-56-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515180-56-00.